Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SITC 2022 | Delta-radiomics predicting response and overall-survival in advanced NSCLC treated with durvalumab

Anant Madabhushi, PhD, Emory University School of Medicine, Atlanta, GA, discusses findings on delta-radiomics predicting response and overall-survival in patient with advanced non-small cell lung cancer treated with durvalumab. A blinded investigation of delta-radiomics was carried out, exploring the radiomic features relating to the heterogeneity of the tumor and the peritumor environment. Changes in the heterogeneity of the tumor and the peritumoral environment were investigated from baseline and following one dose durvalumab to explore predictions of clinically relevant outcomes, such as treatment response. The delta-radiomics were demonstrated to add significant value to exploring features such as tumor size in the context of immuno- and chemotherapy. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.